The 340B Drug Pricing Program, launched by the federal government in 1992, was designed with a noble purpose: to help safety-net hospitals and clinics provide affordable care to low-income and uninsured individuals by mandating steep drug discounts from manufacturers. However, over the decades,
As open enrollment for Affordable Care Act (ACA) plans begins, millions of Americans face uncertainty and looming price hikes, with Congress yet to decide on extending critical subsidies. To dive deeper into this pressing issue, I’m speaking with Dr. Emily Harper, a renowned healthcare policy
Imagine receiving a letter from a hospital informing you that your Social Security number, health records, and financial details have been exposed to an unknown third party due to a cyberattack, a terrifying reality now faced by over 77,000 individuals connected to Sturgis Hospital in Michigan.
What happens when a program designed to help the most vulnerable patients becomes a sprawling system that some say fuels higher healthcare costs? The 340B drug discount initiative, created to ensure low-income individuals access affordable medications, now stands at a critical turning point. In a
Unraveling Healthcare Enrollment Challenges in a Federal Standoff Amid a government shutdown stretching into its fourth week, the Centers for Medicare & Medicaid Services (CMS) confronts a pivotal challenge in sustaining healthcare enrollment for millions of Americans, especially with critical open
Unpacking a Regulatory Roadblock: Why FDA Engagement Matters Now The medical device industry stands at a critical crossroads in 2025, grappling with an unprecedented challenge as a U.S. government shutdown curtailed the Food and Drug Administration's (FDA) physical presence at the annual AdvaMed
